 Basilea Pharmaceutica said Wednesday revenue contributions from Cresemba and Zevtera are expected to amount to about CHF 122 million for fiscal 2022. Total revenue, which includes ... Read Full Story at source may require registration The post Basilea reports 2022 revenue of CHF 148 million appeared first on ForexTV... 